Newsroom

WATERTOWN, Mass.--(BUSINESS WIRE)--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced today that its shares have begun trading on the KOSDAQ market. The IPO marks a significant milestone as the company accelerates the development and global commercialization of its proprietary vascular stabilization pipeline. Founded in Boston in 2018, Ingenia is developing next-generation antibody therapeutics based on technologies ori...

LIMASSOL, Cyprus--(BUSINESS WIRE)--Bermoxel® (praziquantel 600 mg tablets) is now available to healthcare providers across all 27 European Union Member States, offering a supply solution amid the ongoing shortage of Biltricide®, confirmed by the European Medicines Agency. 1 Bermoxel® is manufactured by Medochemie, the only European supplier of Praziquantel 600 mg tablets with a local authorisation and has extended supply across the entire EU. In Germany, Austria, the Netherlands, Belgium and Lu...

DALLAS--(BUSINESS WIRE)--Copart, Inc. (NASDAQ: CPRT) today reported that David J. Berger has joined Copart's Board of Directors, effective August 13, 2026. Mr. Berger, 67, currently serves as a Senior Partner of Wilson Sonsini Goodrich & Rosati, P.C., a law firm, where he has practiced since 1989 and has served as a Partner for more than twenty years. His practice focuses on corporate governance, mergers and acquisitions, and shareholder activism. He has held a number of leadership position...

ALLEN, Texas--(BUSINESS WIRE)--FTK is honored to announce its latest contract award and the launch of an extensive LIHTC renovation project in Newport News, Virginia....

利雅得，沙特阿拉伯--(BUSINESS WIRE)--(美国商业资讯)-- TOURISE今日与Oxford Economics合作发布了一份新报告，题为《在无法重置的世界中展现韧性：常态化动荡时代的旅游业重塑》（Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption）。对过去20年间85起重大危机的分析显示出一个清晰的规律：在冲击不断的当下，未雨绸缪、抢先布局的旅游目的地，其复苏速度比坐等危机爆发的目的地快1.5倍。 沙特阿拉伯旅游部长兼TOURISE主席Ahmed Al-Khateeb阁下表示，“在这个危机接踵而至、无法重回轨道的时代，外部动荡已成为全球旅游业的常态。对各个目的地而言，真正的考验在于能否未雨绸缪应对波动、坚定游客信心，并在危机来临前确保业务的持续运营。” 该报告以当下的中东危机为切入点（海湾地区枢纽机场承担着全球约14%的中转客流量），为投资者与决策者提供了一份切实可行的行动指南，助力其在动荡常态化的全球格局中从容应变。核心发现...

TOYOTA, Japan--(BUSINESS WIRE)--SkyDrive Inc. (“SkyDrive”), a leading compact eVTOL (*1) aircraft manufacturer based in Japan, today announced the signing of a Letter of Intent (LOI) with Gold Coast Helitours, a premier helicopter operator based in the Gold Coast, Australia. This milestone agreement represents SkyDrive's first LOI with an Australian operator regarding the introduction of its aircraft. The parties have reached a basic agreement on the terms for purchasing up to five "SKYDRIVE" e...

WASHINGTON--(BUSINESS WIRE)--Nanochon, een bedrijf dat medische hulpmiddelen ontwikkelt en Chondrograft™ op de markt brengt, een nieuw, gepatenteerd implantaat voor de behandeling van defecten in het gewrichtskraakbeen van de knie, heeft vandaag bekendgemaakt dat het van het Ministerie van Volksgezondheid van Panama toestemming heeft gekregen om in Panama een klinische First-in-Human (FIH)-studie te starten. Het onderzoek evalueert de veiligheid en de werkzaamheid van Chondrograft™ bij patiënte...

WASHINGTON--(BUSINESS WIRE)--Nanochon, empresa de dispositivos médicos que desarrolla Chondrograft™, un innovador implante patentado para tratar lesiones del cartílago articular de la rodilla, anunció hoy que ha obtenido la aprobación del Ministerio de Salud de Panamá para iniciar en el país su primer estudio clínico en humanos (FIH). El estudio evaluará la seguridad y el funcionamiento de Chondrograft™ en pacientes con lesiones focales del cartílago de la rodilla y supone un importante hito en...

WASHINGTON--(BUSINESS WIRE)--Nanochon, une société de dispositifs médicaux développant Chondrograft™, un nouvel implant breveté pour le traitement des lésions du cartilage articulaire du genou, a annoncé aujourd'hui avoir reçu l'autorisation réglementaire du ministère de la Santé du Panama pour lancer sa première étude clinique chez l'Homme (FIH) au Panama. L’étude évaluera la sécurité et les performances de Chondrograft™ chez les patients présentant des lésions chondrales focales du genou, ce...

WASHINGTON--(BUSINESS WIRE)--Nanochon, ein Medizintechnikunternehmen, das Chondrograft™ entwickelt – ein neuartiges, patentiertes Implantat zur Behandlung von Gelenkknorpeldefekten im Knie –, gab heute bekannt, dass es vom Gesundheitsministerium von Panama die behördliche Genehmigung erhalten hat, seine klinische „First-in-Human“-Studie (FIH) in Panama zu beginnen. Die Studie wird die Sicherheit und Wirksamkeit von Chondrograft™ bei Patienten mit fokalen Knorpeldefekten im Knie untersuchen und...